Servier Taps Insilico's Pharma.AI in Multi-Billion Oncology Deal
Insilico Medicine has entered a multi‑year R&D collaboration with Servier to discover and develop novel AI‑designed oncology therapies. The deal will combine Insilico’s Pharma.AI platform with Servier’s global oncology development and commercialization capabilities.
Artificial intelligence (AI)-driven drug discovery company, Insilico Medicine, and pharmaceutical group, Servier, have agreed on a research and development collaboration to discover and advance next‑generation oncology drug candidates. The partnership will use Insilico’s AI‑powered discovery platform, Pharma.AI, while utilizing Servier’s expertise in cancer drug development to tackle challenging oncology targets (1).
Under the terms of the agreement, Insilico is eligible to receive up to USD 32 million in upfront and near‑term R&D payments, with additional potential milestone‑based payments available up to a total of USD 888 million. Insilico will lead AI‑driven target identification, molecule design, and preclinical candidate selection, while Servier will share R&D costs and take responsibility for clinical development, regulatory strategy, and worldwide commercialization of successful candidates.
“This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico’s internally developed and validated AI platform,” said Christophe Thurieau, Executive Director Research at Servier, in a company press release (1).
“As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development,” added Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico Medicine, in the press release (1).
Prior to the agreement, Insilico has built a broad oncology pipeline spanning multiple cancer indications in both moderately novel and established mechanisms of action. Lead assets include ISM6331, a potential best‑in‑class pan‑TEAD inhibitor, and ISM3412, a MAT2A inhibitor — both currently in global, multicenter Phase I clinical trials. An additional four oncology programs with Phase I clinical trials are actively in progress, which have been fully or partially outlicensed to partners.
Insilico’s latest Servier alliance comes as AI‑driven drug discovery gains momentum in oncology R&D. One of the sector’s early movers, Insilico’s recent IPS, raised almost USD 300 million to become the largest biotech listing on the Hong Kong exchange in 2025 by funds raised (2). The company plans to channel most of the proceeds into expanding its AI‑enabled pipeline and platform capabilities.
Servier, meanwhile, is a global pharmaceutical group governed by a non‑profit foundation, allowing it to pursue a long‑term innovation strategy and reinvest profits into R&D rather than meeting short‑term shareholder targets. With oncology being a core focus for Servier, the company has built a portfolio of first‑ and best‑in‑class precision medicines with analysts projecting that the AI in oncology market will grow rapidly over the next decade (3), supporting deeper collaborations between AI‑native biotechs and established pharma groups.
References
Insilico Medicine. Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology. Press Release, Jan. 4, 2026.
Insilico Medicine. Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025’s Largest Hong Kong Biotech IPO. Press Release, Dec. 30, 2025.
Precedence Research. Artificial Intelligence (AI) In Oncology Market Size, Share and Trends 2026 to 2035. Market Research Report, Dec. 23, 2025.